Canada markets closed

Canntab Therapeutics Limited (TBF1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.4340+0.0340 (+8.50%)
At close: 3:38PM CEST
Full screen
Previous Close0.4000
Open0.4200
Bid0.4020 x 0
Ask0.4560 x 0
Day's Range0.4200 - 0.4340
52 Week Range0.1590 - 0.7150
Volume6,000
Avg. Volume281
Market Cap14.717M
Beta (5Y Monthly)1.39
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement
    CNW Group

    Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement

    TORONTO, June 2, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs ("MediPharm") (TSX:LABS.TO - News)(OTCQX:MEDIF - News)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products. Orders under the agreement will be composed of a mix of Canntab's proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths. MediPharm will purchase and distribute cannabis products on a non-exclusive basis across Canada, through licensed provincial dispensaries.

  • Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer
    CNW Group

    Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer

    TORONTO, May 15, 2020 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News)(OTCQB:CTABF - News) (FRA:TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the appointment of Joshi Laxminarayan as Chief Scientific Officer (CSO). In his role as CSO, Mr. Laxminarayan will be responsible for directing Canntab's strategic research and partnership program, and overseeing the Company's ongoing manufacturing and distribution operations.

  • Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference
    CNW Group

    Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference

    TORONTO , May 11, 2020 /CNW/ - Canntab Therapeutics Limited ( CSE:PILL.CN )( OTCQB:CTABF ) ( FRA:TBF1.F ) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene ...